Stocktoria
ELI LILLY & Co LLY
ELI LILLY & Co (LLY) earns a Piotroski F-score of 7/9 (strong financial health). It pays a dividend yielding 0.47% (safety: safe). FY2025 revenue was $65.2B at a 31.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1.87 — grey zone (between the usual thresholds). A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-07 | Truist Securities | Buy (main) |
| 2026-08-06 | Wells Fargo | Overweight (main) |
| 2026-08-06 | Cantor Fitzgerald | Overweight (main) |
| 2026-07-15 | Citigroup | Buy (main) |
| 2026-07-14 | Bernstein | Outperform (main) |
| 2026-07-13 | UBS | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
| ABT | ABBOTT LABORATORIES | 5/9 | 4.85 | 25.1 | +5.7% |
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
About ELI LILLY & Co
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
FAQ
Is LLY financially healthy?
ELI LILLY & Co's Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak).
Does LLY pay a dividend, and is it safe?
Yes. ELI LILLY & Co pays a dividend yielding about 0.47% with a 26.1% payout ratio, rated “safe” for safety.
How profitable is LLY?
In FY2025, ELI LILLY & Co had a net margin of 31.7% and a return on equity of 77.8%.
Is LLY overvalued or undervalued?
ELI LILLY & Co trades at about 53.2× trailing earnings — above its 10-year norm (10-year range 15.7×–111.3×, median 40.1×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for LLY?
The average Wall-Street price target for ELI LILLY & Co is $1,299.01, about 6.5% above the recent price, from 27 analysts (consensus: buy).
Is LLY a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ELI LILLY & Co: a Piotroski F-score of 7/9, a P/E of about 55.1×, a dividend yield of 0.47%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.